Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,670 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
Regulatory Filings
2026-05-19 Hebrew (modern)
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
Report Publication Announcement Classification · 90% confidence The document is an immediate report by BioLineRx (a Form 6-K filing) under Israeli and SEC rules, and it merely announces the publication of the detailed 6-K report (“Form_6-K_19-May-26_isa.pdf”) rather than containing substantive financial or operational data itself. It meets the “menu vs. meal” criteria for a Report Publication Announcement (RPA).
2026-05-19 English
6-K
Foreign Filer Report
2026-05-19 English
6-K - BioLineRx Ltd. (0001498403) (Filer)
Foreign Filer Report
2026-04-28 English
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Regulatory Filings Classification · 90% confidence The document is clearly an SEC Form 6-K (a report of a foreign private issuer) that primarily consists of a press release regarding a clinical trial milestone. It is not a financial report (10-K, IR), not an earnings release, not a management discussion, nor a corporate action (e.g., M&A, dividends). It is a regulatory submission of miscellaneous content under the Securities Exchange Act and therefore falls into the fallback “Regulatory Filings” category.
2026-04-28 English
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Report Publication Announcement Classification · 90% confidence The document is a short immediate report (Form 6-K) from a foreign issuer that merely announces and attaches the full report (“Attached hereto is a report…Form_6-K_28-Apr-26_isa.pdf”). At just ~2,000 characters and explicitly stating the report is attached, it fits the “Report Publication Announcement” category per the “Menu vs Meal” rule rather than being the full substantive report itself.
2026-04-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.